Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sanofi-Aventis S.A. ADR (NQ: SNY ) 55.00 -0.22 (-0.40%) Streaming Delayed Price Updated: 10:36 AM EDT, Aug 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Sanofi-Aventis S.A. ADR < Previous 1 2 ... 9 10 11 12 13 14 15 16 17 ... 29 30 Next > Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ: TLSA) First-In-Class Foralumab Is Showing Promise April 12, 2023 Research is being done into whether there might be treatments that tackle Multiple Sclerosis (MS) through immunosuppression and a reduction of patient neuroinflammation. Anti-CD3 monoclonal antibodies... Via Benzinga Sanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More Information April 11, 2023 Via Benzinga Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow April 11, 2023 A surge in oncology drug development, coupled with increased patient access and early diagnosis, has resulted in a massive increase in global spending on cancer treatments. Due to this, the global... Via Benzinga Zoetis Stock Shows Healthy Growth Along With Puppies, Kittens April 10, 2023 Zoetis stock is trying to complete a flat base with a 176.76 buy point. See if it can break out. Its stock got an upgrade Monday Via Investor's Business Daily 2 Top Healthcare Stocks Defying the Bear Market April 07, 2023 The market sell-off over the past year hasn't stopped these healthcare giants from rallying. Via The Motley Fool Is Sanofi Stock a Buy Now? March 25, 2023 The pharma giant has outperformed the broader market over the past 12 months. Via The Motley Fool Looking Into Sanofi's Recent Short Interest March 23, 2023 Via Benzinga Sanofi (NASDAQ: SNY) Highlighted for Surprising Price Action March 23, 2023 Via Investor Brand Network Novo Nordisk Seeks to Solidify Its Lead in Diabetes Treatment and Crushing the Market April 06, 2023 Its market dominance in diabetes drugs that also help with weight loss is set to continue for at least the next few years. Via The Motley Fool Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity? March 30, 2023 Sanofi and Regeneron's top-selling drug could soon be approved to treat yet another disease. Via The Motley Fool Zoetis Stock Sees IBD Relative Strength Rating Improve To 73 March 27, 2023 Zoetis stock had its Relative Strength Rating upgraded to 73 Monday -- a nice improvement, but still shy of the 80-plus score you look for. Via Investor's Business Daily Sanofi, Regeneron Shares Pop On Big News About COPD Treatment March 27, 2023 Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade. Via MarketBeat Could This Label Expansion Be a Growth Catalyst for Sanofi Stock? March 25, 2023 Sanofi and Regeneron's mega-blockbuster drug could soon be approved in the U.S. for yet another indication. Via The Motley Fool Why Shares of Regeneron Are Rising Thursday March 23, 2023 Regeneron released positive phase 3 trial results for its therapy Dupixent. Via The Motley Fool Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung' March 23, 2023 The companies' Dupixent reduced exacerbations by 30%. Via Investor's Business Daily Acer Therapeutics' Product Acquired From Sanofi Fails In Menopause Study March 17, 2023 Via Benzinga Stock Market Split As Fed Hikes Rates, Banks Keep Tumbling; Nvidia, On Holding In Focus: Weekly Review March 24, 2023 The major indexes showed volatile, divergent action. Via Investor's Business Daily Regeneron Pharmaceuticals Analysts React To Drug Trial Results: Why Whales Are Diving In March 24, 2023 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the Phase 3 trial of Dupixent (dupilumab), developed with Sanofi (NASDAQ: SNY), for uncontrolled chronic obstructive pulmonary disease (COPD) met... Via Benzinga Regeneron Pharmaceuticals Options Traders Betting On Stock Falling This Much By April Expiration March 24, 2023 Sanofi (NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares surged on Thursday after the companies announced primary and all key secondary endpoints were met in a Phase 3 trial... Via Benzinga REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data March 23, 2023 Regeneron Pharmaceuticals (REGN) stock is on the rise Thursday after the company released its latest clinical trial data on Dupixent. Via InvestorPlace BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL) March 23, 2023 From Brodsky & Smith LLC Via GlobeNewswire Apple Jumps Movie Production Bandwagon, Billionaire Jim Ratcliffe Bids For Manchester United, Elon Musk Seeks Funding For SpaceX From Middle-Eastern Fund: Today's Top Stories March 23, 2023 Bloomberg Via Benzinga Why Regeneron Pharmaceuticals And Sanofi Shares Are Trading Higher Today March 23, 2023 Sanofi-Regeneron stocks are trading higher today after their blockbuster drug aced the pivotal COPD trial. Via Benzinga Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories March 20, 2023 Reuters Via Benzinga Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case' March 20, 2023 Via Benzinga Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis March 18, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review March 17, 2023 A market rally is underway, but bank stocks kept tumbling. Via Investor's Business Daily SVB Financial Officially Files For Bankruptcy, Yellen, Powell & Dimon Behind First Republic Bank's $30B Lifeline, Playboy's $5M Loss On Ethereum: Today's Top Stories March 17, 2023 Benzinga Via Benzinga Three Is Company - Sanofi Follows Lilly, Novo Nordisk, Slashes Insulin Product Price By 78% March 17, 2023 Via Benzinga Why Provention Bio Stock Skyrocketed 256% This Week March 16, 2023 Provention Bio is currently a partner of Sanofi. It should soon become a part of the big French drugmaker. Via The Motley Fool < Previous 1 2 ... 9 10 11 12 13 14 15 16 17 ... 29 30 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.